Xenon announces acquisition of new potassium channel modulator for treatment of epilepsy
Xenon Pharmaceuticals reported it has acquired worldwide development and commercialization rights to XEN1101 from 1st Order Pharmaceuticals. XEN1101 is a next-generation Kv7 potassium channel opener that preclinically demonstrated improved pharmacokinetics, selectivity, and pharmacology. April 26, 2017